PsyMed Ventures

NEW Business Trip Episode “Environmental Toxins and Mental Health” with Gurdane Singh Bhutani of MBX Capital In this episode we discuss: - The widespread presence of environmental toxins and their link to diseases like Parkinson's and autism - The field of exposomics and lifetime environmental exposures - Obesogens (chemicals whose exposure makes you fat) - Startups building solutions for better diagnostics, green chemistry, and water treatment - Practical lifestyle changes to reduce exposure to harmful chemicals and improve health Full episode here: https://lnkd.in/g9mbbDNy

Announcing our investment in Ancilia Biosciences, a biotech working on next-gen microbial therapeutics harnessing the power of CRISPR. The microbiome’s impact on human health is undeniable, but many treatments have challenges in effectiveness. Ancilia’s key insight: bacterial therapies often fail to colonize because viruses attack them. Ancilia uses CRISPR’s natural function, which we all know as a gene editing technique in humans. In reality, it is a bacterial defense mechanism against viruses. So, these CRISPR-edited bacteria can survive and engraft, restoring microbial diversity and improving outcomes in many diseases. Ancilia’s platform can address a range of conditions: vaginal bacteriosis, ulcerative colitis, immuno-oncology, and type 2 diabetes. It can (and will) be used to treat mental and brain health. The team’s approach, led by Alexandra Sakatos, is unique. It features the only computational platform that uses CRISPR to map viral-bacterial interactions. They aren’t iterating on existing treatments—they’re creating a new class of medicines! Ancilia is at the nexus of three frontiers: microbiome, virome, and CRISPR. The convergence of frontiers is where magic happens. Happy to co-invest with Vera Schroeder (Safar Partners), Wiz 👨🚀 ‏‏‎ ‎(‏‏‎Spacecadet), Metaplanet, and many others!

Pretty obvious truth: every healthcare GTM channel sucks. - DTC: doesn’t scale - Employers: end-point fatigue. Not adding new vendors - Health systems: slow and no $ to spend on tech - Health insurance: years-long sales cycles and death by 1000 pilots - CMS: wildly bureaucratic. Low reimbursement rates At PsyMed Ventures, we don’t dismiss companies based on GTM channel. All channels work with the right team, product, strategy.

Josh Hardman of Psychedelic Alpha discusses the unique challenges posed by MDMA-assisted therapy as a novel treatment. Full episode here: https://lnkd.in/g2h5Y9Me

future founders: do you have a startup idea in brain and mental health that you’ve been bouncing around and want feedback on? I’m offering an office hour session this Friday 2pm est (on Zoom). DM me for a 10 min slot. No ideas are too early!

Josh Hardman of Psychedelic Alpha shares impacts to payers and reimbursement after the FDA Advisory Committee's no vote to Lykos Therapeutics' MDMA assisted therapy. Full episode here: https://lnkd.in/g2h5Y9Me

Josh Hardman of Psychedelic Alpha shares the most shocking oversight revealed in the latest FDA Advisory Committee meeting on Lykos Therapeutics' MDMA assisted therapy. Full episode here: https://lnkd.in/g2h5Y9Me

NEW Business Trip Episode: "FDA's Advisory Committee says no to MDMA. What's the impact?" with Josh Hardman of Psychedelic Alpha. In this episode, we discuss: - The FDA advisory committee process and its implications for drug approvals - Functional unblinding and expectancy effects in psychedelic clinical trials - Potential impacts on the broader psychedelic medicine industry - The future of psychedelic-assisted psychotherapy protocols - Neuroplastogen development and non-hallucinogenic approaches - Challenges around therapy, safety, and regulatory pathways for psychedelic medicines Tune into the full episode here: https://lnkd.in/gFZDPmgJ

Companies in the neuropsychiatric space can achieve exits (acquisitions or IPOs) within 3-5 years, even before gaining FDA approval. Matias Serebrinsky explains in an SXSW panel "Investing in New Frontiers of Mental Health." Listen to the full episode here: https://lnkd.in/gh4Atu96

PsyMed Ventures GP Matias Serebrinsky joined the New Light Ventures Podcast to share his insights as an emerging manager. Tune into the full episode here: https://lnkd.in/gHSYvk7W